康方生物(09926.HK)治療疼痛注射液臨牀試驗申請獲內地批準
康方生物-B(09926.HK)公佈,其自主研發的創新型神經生長因子(NGF)單克隆抗體(研發代號:AK115)注射液臨牀試驗申請,已獲得國家藥監局藥品審評中心(CDE)批準,用於治療疼痛(包括癌痛)。
由於NGF或其受體Trk A的基因突變會造成先天性痛覺不敏感伴無汗症,因此NGF在痛覺感知和傳導中的作用引起關注。NGF單抗被認爲是疼痛領域最具希望的下一代鎮痛藥物,具備長效安全、無成癮性、無耐藥性等特徵。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.